Obesity & ROSE-010: The Future of Weight Loss Maintenance The GLP-1 Dilemma: Maintaining Weight Loss & Seeking Alternative Weight Loss Options GLP-1 therapies have helped millions lose weight, yet 60-85% of patients discontinue within two years due to: Tolerability Issues Over 50% of GLP-1 patients stop due to nausea, vomiting, or GI side effects Insurance & Cost Barriers Insurance coverage remains inconsistent, limiting long-term access Reaching Their Goa l Many patients lose their desired weight and no longer need daily or weekly injections The Problem
Intensive research efforts are required to meet the demand of identifying novel eryptosis-associated kinases and investigating their potential pharmaceutical targetability
For subcutaneous injections, a standard insulin syringe is typically used
Our company in accordance with the "casting brand, industry leading, quality excellence, continuous innovation" the principle of research and development production of new products, omni-directional to provide customers with more quality services, achieve mutual benefit and win-win cooperation